Intelligence · Patents
Patents expiring in 2042
Annual patent cliff calendar for 2042 — US pharmaceutical patents by expiration date.
- Patents
- 1,738
Quick answer
1,738 indexed pharmaceutical patents have expiration dates in 2042. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 11279933
Antisense oligonucleotides for the treatment of leber congenital amaurosis
granted -
US 11279703
Fused pyrimidine compounds as BRD4 and JAK2 dual inhibitors and methods for use thereof
granted -
US 11285169
Methods for modulating chemotherapeutic cytotoxicity
granted -
US 11285165
Selective high-affinity polydentate ligands and methods of making such
granted -
US 11285154
Methods and compositions for treating cancer
granted -
US 11285153
Substituted pyrimidine piperazine compound and use thereof
granted -
US 11285145
Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4
granted -
US 11285106
Synthetic nanostructures including nucleic acids and/or other entities
granted -
US 11285142
Compositions and methods for identifying and treating dystonia disorders
granted -
US 11286279
Compositions for expanding regulatory T cells (Treg), and treating autoimmune and inflammatory diseases and conditions
granted -
US 11287427
Application of anti-CD39L3 antibodies for use in disease diagnostics and imaging
granted -
US 11285204
Tobamovirus-based virus-like particles and vaccines
granted -
US 11285100
Freeze-dried polymer compositions for mixing with platelet rich plasma to form implants for tissue repair and/or compositions for therapeutic intra-articular injections
granted -
US 11285139
Treatment of CNS conditions
granted -
US 11285178
Fertilized egg isolate and uses thereof
granted -
US 11285129
Treatment of circadian rhythm disorders
granted -
US 11285163
Ophthalmic solution
granted -
US 11286467
System and method for production of fatty acid ethanolamides
granted -
US 11286528
Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
granted -
US 11286486
Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
granted -
US 11285182
Reduction of milk glycans and their degradation products in the neonate gut
granted -
US 11286482
Endosomal cleavable linkers
granted -
US 11286291
Co-stimulatory domains for use in genetically-modified cells
granted -
US 11285184
Cannabidiol alkaline composition
granted -
US 11285175
Targeted disruption of the MHC cell receptor
granted -
US 11286290
Anti-VEGF protein compositions and methods for producing the same
granted -
US 11286307
Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
granted -
US 11286305
Complex comprising anti-transferrin receptor antibody covalently linked to an oligonucleotide that targets DUX4 RNA
granted -
US 11286352
Process for preparation of beads for imaging
granted -
US 11286282
Methods of detection and removal of rhabdoviruses from cell lines
granted -
US 11285210
Buffer formulations for enhanced antibody stability
granted -
US 11285215
Pharmaceutical compositions comprising meloxicam
granted -
US 11285214
Pharmaceutical compositions comprising meloxicam
granted -
US 11286265
Macrocyclic compounds for treating disease
granted -
US 11286264
Macrocyclic compounds and uses thereof
granted -
US 11285213
Pharmaceutical compositions comprising meloxicam
granted -
US 11286463
Reprogramming of aged adult stem cells
granted -
US 11285190
CLEC11a is a bone growth agent
granted -
US 11285194
Combination immunotherapy approach for treatment of cancer
granted -
CA 3192772
AMELIORATION DU BIEN-ETRE PHYSIQUE ET MENTAL DE PATIENTS ATTEINTS D'HYPOPARATHYROIDISME
granted -
US 11291712
Bacterial protein compositions and uses thereof
granted -
US 11293034
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 11291407
Detection of high risk drusen
granted -
US 11293024
Antisense antibacterial compounds and methods
granted -
US 11291707
Polypeptide-polymer conjugates and methods of use thereof
granted -
US 11292842
Anti-PD-1 antibodies for treatment of lung cancer
granted -
US 11291687
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
granted -
US 11293025
Compositions and methods for modulating Ataxin 3 expression
granted
Frequently asked questions
How many pharma patents expire in 2042?
1,738 published patents in our USPTO index have expiration dates falling in calendar year 2042.